Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer

Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is used to profile the circulating DNA of ALTER0303 (evaluating NSCLC clinical antitumor efficacy through anlo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Adv Sci (Weinh)
Asıl Yazarlar: Lu, Jun, Zhong, Hua, Wu, Jun, Chu, Tianqing, Zhang, Lele, Li, Hua, Wang, Qiming, Li, Rong, Zhao, Yizhuo, Gu, Aiqin, Wang, Huimin, Shi, Chunlei, Xiong, Liwen, Zhang, Xueyan, Zhang, Wei, Lou, Yuqing, Yan, Bo, Dong, Yu, Zhang, Yanwei, Li, Baolan, Zhang, Li, Zhao, Xiaodong, Li, Kai, Han, Baohui
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Full Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774020/
https://ncbi.nlm.nih.gov/pubmed/31592412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/advs.201900721
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller